Rani Therapeutics Hldgs (RANI) closed at $0.56 on November 10, 2026, down 2.4% from the previous close, on volume of 527,892 shares (30-day average 497,645).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 1:26 PM ET)
Rani Therapeutics GAAP EPS of -$0.04, revenue of $1.7M
Seeking Alpha News (Mon, 9-Nov 5:30 PM ET)
Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update
Globe Newswire (Mon, 9-Nov 4:05 PM ET)
Rani Therapeutics to Participate in the Chardan Healthcare Conference
Globe Newswire (Tue, 13-Oct 4:05 PM ET)
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Rani Therapeutics to Participate in Upcoming September Conferences
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Market Chameleon (Mon, 20-Oct 6:34 AM ET)
Market Chameleon (Fri, 17-Oct 5:52 AM ET)
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Rani Therapeutics Hldgs trades on the NASDAQ stock market under the symbol RANI.
As of November 10, 2026, RANI stock price declined to $0.56 with 527,892 million shares trading.
RANI has a beta of 1.60, meaning it tends to be more sensitive to market movements. RANI has a correlation of 0.06 to the broad based SPY ETF.
RANI has a market cap of $64.65 million. This is considered a Micro Cap stock.
Last quarter Rani Therapeutics Hldgs reported $2 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $343,400 and exceeded earnings estimates by $.01.
In the last 3 years, RANI traded as high as $8.75 and as low as $.39.
The top ETF exchange traded funds that RANI belongs to (by Net Assets): VTI, VXF, IBBQ, BIB.
RANI has underperformed the market in the last year with a price return of -72.3% while the SPY ETF gained +12.9%. RANI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.3% and -9.3%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
RANI support price is $.55 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RANI shares will trade within this expected range on the day.
